PriceTargets.com logo

Syros Pharmaceuticals - SYRS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.50
  • Forecasted Upside: 201.93%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$4.14 As of 12/8/2023 01:00 AM ET
▼ -0.52 (-11.16%)

This chart shows the closing price for SYRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Syros Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYRS

Analyst Price Target is $12.50
▲ +201.93% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Syros Pharmaceuticals in the last 3 months. The average price target is $12.50, with a high forecast of $15.00 and a low forecast of $7.00. The average price target represents a 201.93% upside from the last price of $4.14.

This chart shows the closing price for SYRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Syros Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/17/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/15/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/14/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/14/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/3/2023Piper SandlerLower TargetOverweight ➝ Overweight$11.00 ➝ $7.00Low
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
8/9/2023Piper SandlerLower Target$16.00 ➝ $11.00Low
5/11/2023JMP SecuritiesLower Target$16.00 ➝ $15.00Low
3/3/2023HC WainwrightReiterated RatingBuy$15.00Low
3/2/2023OppenheimerLower TargetOutperform$15.00 ➝ $13.00Low
1/5/2023Piper SandlerLower TargetOverweight$27.00 ➝ $20.00N/A
12/12/2022JMP SecuritiesReiterated RatingBuy$16.00Low
11/15/2022JMP SecuritiesLower TargetMarket Outperform$40.00 ➝ $16.00Low
11/15/2022OppenheimerLower TargetOutperform$30.00 ➝ $15.00Low
11/15/2022HC WainwrightBoost TargetBuy$20.00Low
8/10/2022OppenheimerLower TargetOutperform$90.00 ➝ $30.00Low
7/12/2022HC WainwrightLower TargetBuy$100.00 ➝ $60.00N/A
5/17/2022HC WainwrightLower TargetBuy$150.00 ➝ $100.00N/A
5/16/2022Alliance Global PartnersLower TargetBuy$100.00N/A
1/10/2022Piper SandlerLower Target$180.00 ➝ $100.00High
11/8/2021HC WainwrightReiterated RatingBuyLow
9/23/2021Roth CapitalBoost TargetBuy$200.00 ➝ $230.00Low
9/21/2021JMP SecuritiesReiterated RatingBuy$200.00High
8/6/2021JMP SecuritiesReiterated RatingBuyHigh
6/24/2021HC WainwrightReiterated RatingBuy$150.00Medium
5/30/2021JMP SecuritiesReiterated RatingBuyLow
3/5/2021Alliance Global PartnersLower Target$180.00 ➝ $140.00Low
11/10/2020Brookline Capital ManagementInitiated CoverageBuy$190.00Low
11/6/2020OppenheimerInitiated CoverageBuy$130.00High
11/4/2020HC WainwrightUpgradeNeutral ➝ Buy$110.00 ➝ $150.00High
10/26/2020Roth CapitalBoost TargetBuy$170.00 ➝ $200.00High
10/25/2020OppenheimerInitiated CoverageBuy$130.00High
9/22/2020Alliance Global PartnersInitiated CoverageBuy$180.00Medium
8/10/2020HC WainwrightReiterated RatingHold$110.00Medium
8/7/2020Piper SandlerBoost Target$140.00 ➝ $180.00Medium
8/6/2020JMP SecuritiesBoost TargetOutperform$160.00 ➝ $200.00Low
6/1/2020OppenheimerInitiated CoverageBuy$110.00Medium
5/29/2020Piper SandlerBoost TargetOverweight$120.00 ➝ $140.00Low
5/8/2020HC WainwrightReiterated RatingHoldHigh
5/7/2020OppenheimerReiterated RatingBuy$110.00High
3/6/2020HC WainwrightReiterated RatingNeutral$100.00 ➝ $80.00High
3/5/2020CowenReiterated RatingBuyHigh
1/17/2020WedbushDowngradeOutperform ➝ Neutral$90.00High
12/18/2019CowenReiterated RatingBuyHigh
11/13/2019HC WainwrightReiterated RatingHold$100.00High
11/12/2019CowenReiterated RatingBuyHigh
10/24/2019CowenReiterated RatingBuyLow
10/18/2019HC WainwrightSet TargetHold$100.00High
10/18/2019JMP SecuritiesLower TargetMarket Outperform$180.00 ➝ $160.00Medium
10/17/2019Piper Sandler CompaniesLower Target$240.00 ➝ $180.00High
7/12/2019Roth CapitalInitiated CoverageBuy$170.00High
5/2/2019HC WainwrightReiterated RatingNeutralLow
4/25/2019WedbushReiterated RatingOutperform$130.00Low
4/10/2019Piper Sandler CompaniesLower TargetOverweight$280.00 ➝ $240.00Low
3/8/2019Roth CapitalSet TargetBuy$140.00High
3/8/2019JMP SecuritiesReiterated RatingMkt Outperform ➝ Mkt Outperform$180.00High
3/8/2019HC WainwrightReiterated RatingHold$100.00High
3/7/2019OppenheimerSet TargetBuy$130.00High
2/14/2019OppenheimerReiterated RatingOutperform$130.00 ➝ $130.00Low
(Data available from 12/9/2018 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/13/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/12/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2023
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/11/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2023

Current Sentiment

  • 5 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Syros Pharmaceuticals logo
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.14
Low: $4.05
High: $4.65

50 Day Range

MA: $2.77
Low: $2.13
High: $4.66

52 Week Range

Now: $4.14
Low: $2.09
High: $5.67

Volume

331,097 shs

Average Volume

109,726 shs

Market Capitalization

$87.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Frequently Asked Questions

What sell-side analysts currently cover shares of Syros Pharmaceuticals?

The following sell-side analysts have issued research reports on Syros Pharmaceuticals in the last twelve months: HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, and StockNews.com.
View the latest analyst ratings for SYRS.

What is the current price target for Syros Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Syros Pharmaceuticals in the last year. Their average twelve-month price target is $12.50, suggesting a possible upside of 201.9%. JMP Securities has the highest price target set, predicting SYRS will reach $15.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $7.00 for Syros Pharmaceuticals in the next year.
View the latest price targets for SYRS.

What is the current consensus analyst rating for Syros Pharmaceuticals?

Syros Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SYRS will outperform the market and that investors should add to their positions of Syros Pharmaceuticals.
View the latest ratings for SYRS.

What other companies compete with Syros Pharmaceuticals?

Other companies that are similar to Syros Pharmaceuticals include Anebulo Pharmaceuticals, Eyenovia, Cara Therapeutics, Spruce Biosciences and NGM Biopharmaceuticals. Learn More about companies similar to Syros Pharmaceuticals.

How do I contact Syros Pharmaceuticals' investor relations team?

Syros Pharmaceuticals' physical mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 744-1340 and its investor relations email address is [email protected]. The official website for Syros Pharmaceuticals is www.syros.com. Learn More about contacing Syros Pharmaceuticals investor relations.